Growing IP Portfolio Signals Further Opportunity for Expansion of Company’s Technology Platform
EDEN PRAIRIE, MINN. - October 14, 2025 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced successful additions to the company’s growing patent portfolio: the first granted patent in Europe and both an issued patent and a Notice of Allowance in the United States.
On September 29, 2025, the United States Patent and Trademark Office (“USPTO”) issued a Notice of Allowance for U.S. Patent Application 17/860,232, titled “Probe Devices with Temperature Sensors and Related Systems and Methods,” which covers novel electrode devices having at least one electrode contact and a temperature sensor.
A Notice of Allowance is issued by the USPTO after examination of a patent application and a determination that a patent should be granted from the application. NeuroOne anticipates the issuance of the patent in the coming months.
In addition, on October 1, 2025, European Patent 4013481, titled “Spinal Cord Stimulation Systems, Methods, and Devices” was granted by the European Patent Office. The patent covers novel spinal cord stimulation devices having a deployable electrode array body.
Finally, on October 7, 2025, U.S. Patent 12,435,407, titled “Methods for Making Probe Devices and Related Devices,” was issued by the U.S. Patent and Trademark Office. The patent covers novel methods of making neural probe and spinal cord stimulation devices, including specific steps for the arrangement of probe components and deposition of electrode contact material.
In addition to the allowed U.S. patent application, the granted European patent, and the issued U.S. patent, NeuroOne’s patent portfolio includes four additional issued U.S. patents, seven additional pending U.S. applications, and eight pending foreign applications covering a wide variety of thin-film electrode technologies, including both neural and spinal cord electrodes having unique structures to optimize the functionality and minimized profile of those electrodes.
“NeuroOne has made tremendous progress expanding our robust patent portfolio. Our goal is to continue to grow our technology platform to broader use cases and applications,” said Dave Rosa, chief executive officer, NeuroOne. “Temperature Control is an integral feature of our OneRF Ablation System® that provides a critical safety measure for brain ablations for patients suffering from seizures. We are also excited to receive our first European patent that features our percutaneously placed paddle electrode, designed to save patients from having to undergo a surgical incision to treat lower back pain.”
About NeuroOne
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, monitoring, ablation, drug delivery and stimulation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “forecasts,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the anticipation of the issuance of the patent, and our business strategy, market size, and other potential growth opportunities. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations for the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
Caution: Federal law restricts this device to sale by or on the order of a physician.
IR Contact
MZ Group - MZ North America
NMTC@mzgroup.us
